Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Free Cash Flow: 2017-2025

Historic Free Cash Flow for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to -$40.6 million.

  • Cidara Therapeutics' Free Cash Flow fell 10.61% to -$40.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$132.9 million, marking a year-over-year increase of 16.99%. This contributed to the annual value of -$176.7 million for FY2024, which is 670.21% down from last year.
  • Per Cidara Therapeutics' latest filing, its Free Cash Flow stood at -$40.6 million for Q3 2025, which was up 0.84% from -$41.0 million recorded in Q2 2025.
  • Cidara Therapeutics' 5-year Free Cash Flow high stood at $28.0 million for Q3 2022, and its period low was -$103.9 million during Q2 2024.
  • Its 3-year average for Free Cash Flow is -$27.6 million, with a median of -$21.9 million in 2025.
  • Per our database at Business Quant, Cidara Therapeutics' Free Cash Flow skyrocketed by 333.34% in 2022 and then crashed by 3,925.52% in 2024.
  • Cidara Therapeutics' Free Cash Flow (Quarterly) stood at -$14.9 million in 2021, then tumbled by 40.60% to -$21.0 million in 2022, then surged by 38.60% to -$12.9 million in 2023, then tumbled by 128.02% to -$29.4 million in 2024, then fell by 10.61% to -$40.6 million in 2025.
  • Its Free Cash Flow was -$40.6 million in Q3 2025, compared to -$41.0 million in Q2 2025 and -$21.9 million in Q1 2025.